Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Abstract

Ide-cel induced responses in a majority of heavily pretreated patients with refractory and relapsed myeloma; MRD-negative status was achieved in 26% of treated patients. Almost all patients had grade 3 or 4 toxic effects, most commonly hematologic toxic effects and cytokine release syndrome. (Funded by bluebird bio and Celgene, a Bristol-Myers Squibb company; KarMMa ClinicalTrials.gov number, NCT03361748.).

Keywords

Affiliated Institutions

• Sarah Cannon US
• Université de Lille FR
• University of Milan IT
• GNA University IN
• Institute for Translational Research in Inflammation
• University Hospital Heidelberg DE
• Universitätsklinikum Tübingen DE
• Ospedale Papa Giovanni XXIII IT
• Universitätsklinikum Würzburg DE
• Hackensack University Medical Center US
• University Medical Center Hamburg-Eppendorf DE
• Bristol-Myers Squibb (Sweden) SE
• Universität Hamburg DE
• Navarre Institute of Health Research ES
• Emory University US
• VA Boston Healthcare System US
• Icahn School of Medicine at Mount Sinai US
• Institut Català d'Oncologia ES
• Princess Margaret Cancer Centre CA
• Massachusetts General Hospital US
• Centro de Investigación Biomédica en Red de Cáncer ES
• Dana-Farber Cancer Institute US
• The University of Texas Southwestern Medical Center US
• Tennessee Oncology US
• National Center for Tumor Diseases DE
• University of California, San Francisco US
• Clinica Universidad de Navarra ES
• Mayo Clinic in Arizona US
• Heidelberg University DE

Related Publications